港股创新药业绩强劲复苏，全市场规模最大的港股创新药ETF（513120）受关注

Group 1 - The core viewpoint of the articles highlights the significant growth in profits for innovative drug and CXO companies in Hong Kong, driven by favorable factors such as BD transactions, breakthroughs in AI pharmaceutical technology, and optimized healthcare policies [1] - Approximately 110 Hong Kong-listed biopharmaceutical companies released interim performance reports, with nearly 70 companies reporting year-on-year revenue growth, and about 10 companies achieving revenue growth exceeding 100% [1] - The China Hong Kong Innovative Drug Index (CNY) has seen a cumulative increase of 106.5% year-to-date, outperforming the Hang Seng Composite Index by 77.83 percentage points as of September 4 [1] Group 2 - The largest Hong Kong innovative drug ETF (513120) has experienced a year-to-date increase of over 107%, ranking first among Wind's secondary investment types, with its latest scale surpassing 20.5 billion [1] - The ETF tracks the China Hong Kong Innovative Drug Index, benefiting from both low valuation advantages and strong fundamental earnings [1] - The index's price-to-earnings ratio stands at 35.93 times, positioned at the 37th percentile historically, indicating attractive valuation [1] Group 3 - Analysts from Wanlian Securities note that apart from a few large hybrid innovative drug leaders, some biotech companies like 3SBio, Innovent Biologics, and BeiGene have already achieved profitability [2] - These three innovative drug giants are among the top ten weighted stocks in the Hong Kong innovative drug ETF (513120), which collectively accounts for over 70% of the index's weight [2] - Institutions are optimistic about the sustainable growth of the innovative drug sector, with expectations for continued performance in the second half of the year [2] Group 4 - The Hong Kong innovative drug ETF (513120) offers an efficient way for investors to participate in the biotech sector, combining both technology and pharmaceutical attributes, making it suitable for medium to long-term capital allocation [3] - The ETF provides significant risk diversification compared to individual stock investments and can adapt flexibly to market style rotations [3] - As more innovative drug companies reach profitability between 2025 and 2027, the growth potential of the sector is expected to expand further [3]